wersja polska printable version
	kwartalnik ISSN 0500-7208 Czasopismo punktowane przez KBN, Index Copernicus oraz w bazie GBL

1. Black PC, Brown GA, Dinney CP: Molecular markers of urothelial cancer and their use in the monitoring of superficial urothelial cancer. J Clin Oncol 2006, 24, 5528-35.
2. Adam R.: Cyclooxygenase-2 in transitional cell carcinoma – a legitime target? J Urol 200 177,818-819.
3. McKiernan JM, Masson P, Murphy AM et al: Phase I trial of intravesical Docetaxel in the management of superficial bladder cancer refractory to standard intravesical therapy. J Clin Oncol 2006, 24, 3075-3080.
4. Lebret Th, Watson RWG, Molinie V et al: HSP90 expression, a new predictor factor for BCG response in stage Ta-T1 grade 3 bladder tumours. Eur Urol 2007, 51, 161-167.
5. Harland SJ, Kynaston H, Grigor K et al: A randomised trial of radical radiotherapy for the management of pT1G3 NXM0 transitional cell carcinoma of the bladder. J Urol 2007, 178, 807-813.
6. Shariat SF, Ashfaq R, Karakiewicz PI et al: Survivin expression is associated with bladder cancer presence, stage, progression, and mortality. Cancer 2007, 109, 1106-1113.
7. Zhao J, He D, He H et al: Primary application study in early diagnosis of bladder cancer by survivin molecular beacons. Urology, 2007, 70, 60-64.
8. Sternberg C: Muscle invasive and metastatic bladder cancer. Annals of Oncology 2006, 17, suppl 10, 23-30.
9. International bladder cancer nomogram consortium. Postoperative nomogram predicting risk of reccurence after radical cystectomy for bladder cancer. J Clin Oncol 2006, 24, 3967-3972.
10. Koppie TM, Vickers AJ, Vora K et al: Standardization of pelvic lymphadenectomy performed at radical cystectomy. Cancer 2006, 107, 2368-2374.
11. Wright JL, Porter MP, Li ChI et al: Differences in survival among patients with urachal and nonurachal adenocarcinomas of the bladder. Cancer 2006, 107, 721-728.
12. Galsky MD, Iasonos A, Mironov S et al: Prospective trial of ifosfamide, paclitaxel and cisplatin in patients with advanced non-transitional cell carcinoma of the urothelial tract. Urology 2007, 69, 255-259.
13. Schumacher MC, Scholz M, Weise ES et al: Is there an indication for frozen section examination of the ureteral margins during cystectomy for transitional cell carcinoma of the bladder. J Urol 2006, 176, 2409-2413.
14. Ganesh VR, Tal R, Vickers A et al: Significance of intraoperative ureteral evaluation at radical cystectomy for urotelial cancer. Cancer 2006, 107, 2167-2172.
15. Rades D, Walz J, Schild SE et al: Do bladder cancer patients with metastatic spinal cord compression benefit from radiotherapy alone. Urology 2007, 69, 1081-1085.
16. Webster WC, Lohse ChM, Tompson RH et al: Mononuclear cell infiltration in clear-cell renal cell carcinoma independently predicts patient survival. Cancer 2006, 107, 46-53.
17. Araki K, Igarashi T, Tobe T et al: Serum immunosuppressive acid protein doubling time as a prognostic factor for recurrent renal carcinoma after nephrectomy. Urology 2006, 68, 1178-1182.
18. Kouba E, Smith A, McRackan D et al: Watchful waiting for solid renal masses, insight into the natural history and results of delayed intervention. J Urol 2007, 177 466-470.
19. Crispen PL, Uzzo RG: The natural history of untreated renal masses. BJU International 2007, 99, 1203-1207.
20. Van Popel H, Joniau S: How important are surgical margins in nephronsparing surgery? Eur Urol 2007, suppl 6, 533-539.
21. Kunkle DA, Crispen PL, Li T et al: Tumor size predicts synchronous metastatic renal cell carcinoma, implications for surveillence of small renal masses. J Urol 2007, 177, 1692-1697.
22. Toyoda Y, Shinohara N, Harabayashi T et al: Survival and prognostic classification of patients with metastatic renal cell carcinoma of bone. Eur Urol 2007, 52, 163-169.
23. Thompson RH, Frank I, Lohse ChM et al: The impact of ischemia time during open nephron sparing surgery on solitary kidneys, a multi-institutional study. J Urol 2007, 177, 471-476.
24. Uribe PS, Costabile RA Peterson AC: Progression of renal tumors after laparoscopic radiofrequency ablation. Urology 2006, 68, 968-971.
25. Ficcara V, Galfano A, Guille F et al: A new staging system for locally advanced (pT3-4) renal cell carcinoma, a multicenter European study including 2000 patients. J Urol 2007, 178, 418-424.
26. Ueno NT, Cheng YC: The future of allogenic hematopoietic stem cell transplantation for metastatic renal cell carcinoma in the era of target-specific therapy. Bone marrow transplantation? 2006, 38, 711-714.
27. Kayes O, Minhas S, Allen C et al: The role of magnetic resonance imaging in the local staging of penile cancer. Eur Urol 2007, 51, 1313-1319.
28. Lont AP, Kroon BK, Gallee MPW et al: Pelvic lymph node dissection for penile carcinoma, extent of inguinal lymph node involvement as an indicator for pelvic lymph node involvement and survival. J Urol 2007, 177, 947-952.
29. Pettersson A, Richiardi L, Nordenskjold A et al: Age at surgery for undescended testis and risk of testicular cancer. N Engl J Med 2007, 356, 1835-1841.
30. Haugnes HS, AassN, Fossa SD et al: Components of the metabolic syndrome in long-term survivors of testicular cancer. Ann Oncol 2007, 18, 241-248.
31. Leonhartsberger N, Gozzi Ch, Akkad T et al: Organ-sparing surgery does noet lead to greater antisperm antibody levels than orchidectomy. BJU Intern 2007, 100, 371-74.
32. Morgentaler A: Testosterone deficiency and prostate cancer, emerging recognition of an important and troubling relationship. Eur Urol 2007, 52, 696-701.
33. Morris BJ, Wskett J, Bailist SA: Case number and financial impact of circumcision in reducing prostate cancer. BJU International 2007, 99, 5-6.
34. Thompson IM, Lucia MS, Redman MW et al: Finasteride decreases the pisk of prostatic intraepithelial neoplasia. J Urol 2007, 178, 107-110.
35. Loeb S, Roehl KA, Catalona WJ et al: Prostate specific antygen velocity treshold for predicting prostate cancer in young men. J Urol 2007, 177, 899-902.
36. Salama G, Noirot O, Bataille V et al: Seasonality of serum prostate-specific antigen levels, a population based study. Eur Urol 2007, 52, 708-714.
37. Graif T, Loeb S, Kimberly A et al: Under diagnosis and over diagnosis of prostate cancer. J Urol 2007, 178, 88-92.
38. Al-Azab R, Toi A, Lockwood G et al: Prostate volume is strongest predictor of cancer diagnosis at transrectal ultrasoun-guided prostate biopsy with prostate-specific antigen values between 2.0 and 9.0 ng/ml. Urology 2007, 69, 103-107.
39. Jones JS. Saturation biopsy for detecting and characterising prostate cancer. BJU Intern 2007, 99, 1340-1344.
40. Briganti A, Shariat SF, Chunt FK-H et al: Differences in the rate of lymph node invasion in men with clinically localized prostate cancer might be related to the continent of origin. BJU Intern 2007, 100, 528-532.
41. Jones JS. Urologists, be aware of significant risk to stoping anticoagulants in patients with drug-eluting coronary stents. BJU Intern 2007, 99, 1330-1331.
42. Celhay O, de la Taille A, Salomon L et al: Fluctuating prostate-specific antigen levels in patients with initial negative biopsy, should we be reassured. BJU Intern 2007, 99, 1028-1230.
43. Leman ES, Cannon GW, Trock BJ et al: EPCA-2, A highly specific serum marker for prostate cancer. Urology 2007, 69, 714-720.
44. Marks LS, Fradet Y, Deras IL et al: POCA3 molecular urine assay for prostate cancer in men undergoing repeat biopsy. Urology 2007, 69, 532-535.
45. Vis AN, Roemeling S, Kranse S: Should we replace the Gleason score with the amount of high grade prostate cancer. Eur Urol 2007, 51, 931-939.
46. Kupelian PA, Reddy ChA, Reuther AM et al: Aggressiveness of familial prostate cancer. J Clin Oncol 2006, 24, 3445-3450.
47. Speight JL, Roach III M: Advances in the treatment of localized prostate cancer, the role of anatomic and functional imaging in men managed with radiotherapy. J Clin Oncol 2007, 25, 987-995.
48. Stephenson AJ, Kattan MW, Eastham JA et al: Defining biochemical recurrence of prostate cancer after radical prostatectomy, a proposal for standarized definition. J Clin Oncol 2006, 24, 3973-3978.
49. Shukla-Dave A, Hricakt D, Kattan M.W et al: The utility of magnetic resonance imaging and spectroscopy for predicting insignificant prostate cancer, a initial analysis. BJU Intern 2007, 99, 786-793.
50. Bastian PJ, Gonzalgo ML, Aronson WJ et al: Clinical and pathologic outcome after radical prostatectomy for prostate cancer patients with a preoperative Gleason sum of 8 to 10. Cancer 2006, 107, 1265-1272.
51. Freedland SJ, Partin AW, Humphreys EB et al: Radical prostatectomy for clinical stage T3a disease. Cancer 2007, 109, 1273-1278.
52. Abe T, Shinohara N, Harabayashi T et al: Postoperative inguinal hernia after radical prostatectomy for prostate cancer. Urology 2007, 69, 326-329.
53. Choi JM, Nelson CJ, Stasi J et al: Orgasm associated incontinence (Climacturia) following radical pelvic surgery, rates of occurence and predictors. J Urol 2007, 177, 2223-2226.
54. Descazeaud A, Debre B, Flam TA: Age difference between patient and partner is a predictive factor of potency rate following radical prostatectomy. J Urol 2006, 176, 2594-2598.
55. Stephenson AJ, Scardino PT, Kattan MW et al: Predicting the outcome of salvage radiation therapy for recurrent prostate cancer after radical prostatectomy. J Clin Oncol 2007, 25, 2035-2041.
56. Reuter MA, Epple W, Ungemach G et al: Transurethral resection for prostate cancer (TURPC), a radical procedure. Experience with 1084 cases. Urology, Suppl 5A, 2006, 68, 24-25.
57. Van Tol-Geerdink JJ, Stalmeier PLM, van Lin ENJT et al: Do patients with localized prostate cancer teratment really want more aggressive treatment. J Clin Oncol 2006, 24, 4581-4586.
58. Frank SJ, Pisters LL, Davis J et al: An assessement of quqlity of life following radical prostatectomy, high dose external beam radiation therapy and brachytherapy Iodine implantation as monotherapies for localized prostate cancer. J Urol 2007, 177, 2151-2156.
59. Leibovici D, Spiess PhE, Agarwal PK et al: Prostate Cancer progression in the presence of undetectable or low serum prostate-specific antigen level. Cancer 2007, 109, 198-204.
60. D’Amico AV, McLeod DG, Carroll PR et al: Time to undetectable prostatespecific antigen (PSA) after androgen suppression therapy for postoperative or postradiation PSA recurrence and prostate cancer-specific mortality. Cancer 2007, 109, 1290-1295.
61. D’Amico AV: Toward the optimal use of androgen suppression therapy in radiotherapeutic management of prostate cancer. J Clin Oncol 2007, 25, 8-9.
62. D’ Amico AV, Denham JW, Bolla M et al: Short versus long-term androgen suppression plus external beam radiation therapy and survival in men of advanced age with node-negative high-risk adenocarcinoma of the prostate. Cancer 2007, 109, 2004-2010.
63. D’Amico AV, Loffredo M, Renshaw AA et al: Six-month androgen suppression plus radiation therapy compared with radiation therapy alone for men with prostate cancer and a rapidly increasing pretreatment prostatespecific antigen level. J Clin Oncol 2006, 24, 4190-4195.
64. Haliloglu A, Baltaci S, Yaman O: Penile lenght changes in men treated with androgen suppression plus radiation therapy for local or locally advanced prostate cancer. J Urol 2007, 177, 128-130.
65. Sarosdy MF: Testosterone replacement therapy for hypogonadism after teratment of early prostate cancer with brachyterapy. Cancer 2007, 109, 536-541.
66. Dall’Rea MA, Hampson MB, Hsi RA et al: Hyperbarbic oxygen therapy for radiation induced proctopathy in men treated for prostate cancer. J Urol 2006, 176, 87-90.
67. Pomerantz M, Manola J, Taplin M-E et al: Phase II study of low dose and high dose conjugated estrogen for androgen independent prostate cancer. J Urol 2007, 177, 2146-2150.
68. Harris JP, Dawkins GPC: The role of tamoxifen in reducing bicalutamideinduced gynaecomastia and brest pain. BJU Intern 2006, 97, 243-244.
69. Salomon L, Feuillu B, Petit J et al: Evaluation du taux de PSA seriquedes sujets en etat de mortr encephalique de plus de 50 ans avant prelevement d’organes, risque de transmission du cancer de prostate et don d’organes. Enquette de transplantation et de cancerologie de l’Association Francaise d’Urologie. Prog Urol 2007, 17, 828-831.

Andrzej Borkowski
Klinika Urologii AM
ul. Lindleya 4
02-005 Warszawa
tel. (022) 502 17 23
urolwa@warman.com.pl